Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

por Zettl, Markus, Wurm, Melanie, Schaaf, Otmar, Mostböck, Sven, Tirapu, Iñigo, Apfler, Ilse, Lorenz, Ivo C., Frego, Lee, Kenny, Cynthia, Thibodeau, Michael, Oquendo Cifuentes, Elisa, Reschke, Markus, Moll, Jürgen, Kraut, Norbert, Vogt, Anne, Sedgwick, Jonathon D., Waizenegger, Irene C.
Publicado 2022